this tells me we are in the early stages of changing consumer behavior specifically for biotech.

for decades, biotech has largely operated behind the walls of hospitals, labs and physician offices. the consumer was usually the endpoint of the innovation process, not an active participant in creating demand for it. this has led the to what some experts are calling consumer biotech.

So what is consumer biotech?

Subscribe now

historically, when we said "biotech," we probably thought about therapeutics, diagnostics, biologics, drug discovery and clinical research. However:

Consumer biotech is the growing category of biological products, diagnostics, data and interventions that allow individuals to actively participate in understanding, monitoring or changing their biology.

That includes:

• GLP-1s

• CGMs outside traditional diabetes management

• at-home diagnostics

• genetic testing

• reproductive health testing

• microbiome products/testing

• wearable-derived metabolic data

• potentially epigenetic/biological-age testing

• personalized nutrition

• eventually interventions around aging

its important to note that consumer biotech isn’t necessarily the same as DTC healthcare. DTC is distribution and marketing model. consumer biotech is almost like a shift in who participates in the biology decision-making process.

for most of modern medicine, the patient was relatively passive.

today, the individual is increasingly showing up with questions, data, hypotheses and expectations.

that is a very different healthcare consumer.

the patient is becoming an active participant in their biology.

GLP-1s didn't just create a drug market. They created a consumer market.

1. The problem was already culturally legible

everyone understands weight.

you don’t have to explain what a scale is. You don’t have to explain what losing 20 pounds means.

compare that with many biotech innovations where the consumer doesn’t even know they have the problem being solved.

2. The outcome was visible

weight loss creates an extraordinarily powerful feedback loop.

You can:

• see it

• measure it

• photograph it

• talk about it

• share it

• compare it

3. The product fit naturally into consumer behavior

• weekly injection

• telehealth

• apps

• online communities

• influencers

• before-and-after stories

• social media

GLP-1s increasingly became accessible through consumer-facing telehealth platforms, and the category has moved into social media, apps and even anticipated oral formulations that could further reduce friction. (Reuters)

But is the GLP-1 DTC playbook actually a good thing?

it is powerful. It is not inherently good.

DTC can democratize awareness and access. But it can also turn medicine into demand generation.

and GLP-1s show both sides.

on one side, consumer demand has pushed metabolic health into mainstream conversation.

on the other, the FDA has warned telehealth companies about misleading marketing of compounded GLP-1s, while the FTC has taken action over deceptive pricing, testimonials and weight-loss claims.

that an important distinction

Consumerization can increase agency without necessarily increasing understanding.

those are not the same thing.

someone can be extremely informed about a drug’s existence and still have a poor understanding of:

• who should take it

• long-term risks

• side effects

• weight regain

• muscle loss

• nutrition

• appropriate monitoring

• interactions with other conditions

• whether they actually need it

this is the gap.

This leads me to: biotech needs a consumer education playbook

I don’t mean work through patient advocacy groups or a heavy heavy ads marketing budget etc. but

How do we make more people interested in taking care of their biology before they become patients?

GLP-1s have demonstrated that consumers will engage with complicated biology when:

1. the problem feels personally relevant

2. the outcome is tangible

3. the science can be explained simply

4. the intervention is accessible

5. there is social proof

6. there is continuous feedback

7. there is a community around it

that’s the playbook worth learning from and optimizing.

traditional healthcare often looks like:

Symptom → Doctor → Diagnosis → Treatment

the emerging consumer healthcare model can look more like:

Concern → Search → Content → Community → Data → Doctor → Treatment

Where else could this work?

there is already a lot of movement in these verticals. Wearables have been paving the path for this with a lot of consumer interest driven towards tracking and collecting data.

Why are people suddenly interested in seeing their data and understanding?

because the consumer wants feedback.

Measure → understand → change → measure again.

that is the consumer health flywheel.

However, the missing layer: interpretation

This is probably the biggest gap I’d highlight.

We are rapidly creating a world where consumers can generate enormous amounts of biological data.

But:

Data ≠ understanding.

And:

Understanding ≠ action.

A consumer might know their:

• glucose

• sleep score

• VO₂ max

• biological age

• microbiome

• hormone levels

• genetic variants

but what do they actually do with that information? this creates an enormous opportunity between the diagnostic and the intervention.

the future consumer stack could look something like:

Measure → Interpret → Personalize → Intervene → Monitor

GLP-1s occupy the intervention layer. today, many companies own only one piece of that chain.

the next generation may own several.

and that could fundamentally change how healthcare is delivered.

Which brings me to longevity

I would not say “everything ultimately fits into longevity.”

because longevity can become a lazy umbrella for everything from supplements to diagnostics to cancer therapeutics.

Instead :

there is a common destination emerging across many of these categories: not simply treating disease, but extending the years in which people remain healthy, functional and independent.

that’s healthspan, not just lifespan.

so basically:

GLP-1s → metabolic health
CGMs → metabolic awareness
Strength → muscle preservation
Sleep → recovery
Women’s health → reproductive + hormonal health
Cardiovascular monitoring → prevention
Diagnostics → earlier intervention
Personalized nutrition → metabolic function

and eventually:

Longevity becomes less of a standalone category and more of the outcome that these categories are collectively moving toward.

The next GLP-1 isn’t necessarily a GLP-1

the biggest lesson from GLP-1s may have nothing to do with GLP-1s.

they demonstrated that biotech can become culturally relevant. they demonstrated that consumers will learn complicated biology when they believe it can meaningfully change their lives. they demonstrated that healthcare demand can be created outside the doctor’s office.

and they demonstrated the power of a flywheel:

The question now is:

What is the next biological problem we can build that flywheel around?

And importantly:

Can we do it without sacrificing evidence, nuance and medical oversight?

Subscribe now

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science with a global lens.

Here are a few reads I bookmarked in July and actively tried reading more substacks to gain more nuanced insights on some headlines.

Biotech startup funding gap widens despite rebound in VC investment

I’ve noticed a lot of people saying “funding is back.” I don’t think that’s quite true.

Capital is returning but it’s flowing into companies that are already significantly de-risked, have late-stage assets, or have a compelling AI story. That’s a very different environment from saying early-stage biotech is suddenly easy to finance again.

Stay Humble: Life Sciences as a Small Slice of an Increasingly Big Venture Pie

Aimee Raleigh from Atlas Venture made one of my favorite observations earlier this year - Biotech isn’t having a bad year. The XBI is performing well. IPO activity has returned. Private financings continue to happen. Yet life sciences continues to shrink as a percentage of overall venture capital because AI investments have exploded so dramatically.

This is such an important distinction.

Both statements can be true:

• biotech is improving,

• biotech is receiving a smaller share of venture dollars.

GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale

What interests me isn’t another company claiming GLP-1s can treat everything.

It’s that clinicians themselves are beginning to broaden the conversation.

That’s a much stronger signal than marketing.

The bigger question now is whether reimbursement keeps pace with clinical enthusiasm because payer adoption is often where promising therapies slow down.

Drug Discovery Industry Roundup

There’s an important distinction emerging.

Most AI companies are building software for biotech.

Anthropic appears interested in actually participating in the discovery workflow itself.

Whether that proves faster or more effective than companies like Insilico which have spent nearly a decade building dedicated drug discovery platforms remains to be seen.

It’s a very different strategic bet.

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

One of the sharper opinion pieces I read this month argued that increasingly capable reasoning models could fundamentally change the competitive advantage of TechBio startups.

If general-purpose AI begins solving many computational biology problems out of the box, startups can no longer differentiate themselves simply by saying they have “better AI.”

Instead, they’ll need differentiated datasets, biological validation, proprietary experiments, and clinical evidence.

Functional and dysfunctional T regulatory cell states in human tissues in RA and other autoimmune arthritic diseases

One paper that caught my attention this month came from Nature Immunology.

Rather than focusing on another incremental biomarker, it explores how immune responses are regulated in ways that could influence future therapeutic strategies.

Worth reading because they quietly reshape how researchers think about disease mechanisms years before new therapies appear.

Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates

Eli Lilly announced a $3.8B acquisition of Atai Beckley, putting another spotlight on psychedelic therapeutics.

Thus validates interest but not necessarily a sustained M&A cycle.

The companies that survive over the next few years will likely be the ones producing convincing clinical data rather than relying on sector excitement.

MIDI Health is Valued at $1 Billion

This was probably my favorite opinion piece of the month.

An OB-GYN breaks down Midi Health’s $1B valuation and questions whether evidence-based menopause care alone supports venture-scale returns.

Her argument is that many digital health companies eventually need to expand into wellness products and adjacent revenue streams because medically indicated hormone therapy has a finite market.

The Peptide Playbook

This Substack walks through how peptides have evolved from niche therapeutics into one of biotech’s hottest commercial categories.

There’s usually a decade of platform building, manufacturing improvements, clinical validation, and regulatory learning before they suddenly appear “everywhere.”

We’re seeing that same pattern play out with peptides today.

The Future Pharma Company Won’t Look Like Today’s Pfizer

I liked that it shifts the conversation away from "Can AI solve biology?" to "Can AI reinvent the way we develop medicines?" It also raises an interesting question: will the pharma companies of the future look more like today's tech companies, or will the winners be those that combine AI with proprietary biological data, clinical expertise, and regulatory know-how? It's a perspective I hadn't seen framed this clearly before.

Subscribe now

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science with a global lens.

Happy reading!

1. Protein coffee, CBD soda: the functional beverage boom

This isn’t really a beverage story, it’s a distribution story. Consumers aren’t waking up wanting “functional beverages”; they’re already buying coffee, soda and hydration products. Health is simply becoming another feature layered onto existing habits. That’s a much bigger opportunity than convincing someone to take another supplement.

What I kept coming back to, though, is the evidence gap. The article mentions everything from protein to adaptogens to lion’s mane, but barely touches on whether these ingredients are present at clinically meaningful doses. As formulation becomes easier, I think the real differentiator won’t be having functional ingredients, it’ll be proving they actually do something.

2. Isomorphic Labs - Not Built to Be a Biotech and It’s Fine

I liked the central argument here: people keep trying to value AI drug discovery companies like biotech companies, when many of them may end up looking more like infrastructure businesses. Partnership economics matter far more than billion-dollar milestone headlines.

The question I’m left with is whether proprietary biology compounds fast enough to stay ahead of increasingly capable open-source models. If AI capabilities become commoditized, the moat shifts to data, workflows and execution not the model itself. .

3. Claude Science: an AI workbench for scientists

This feels less like another AI model launch and more like AI becoming embedded into the scientific workflow itself. We’re moving from “ask an LLM a question” toward workbenches that help researchers design experiments, analyze literature and reason through hypotheses.

That said, almost every productivity claim comes from early users inside Anthropic’s ecosystem. That’s useful directional evidence, but I’d wait for independent labs to publish reproducible outcomes before treating the reported time savings as established fact.

4. Target identification and assessment in the era of AI

One sentence stood out more than anything else: despite all the excitement around AI, no drug originating from AI-driven target identification has reached approval yet.

That doesn’t make the technology less interesting, it simply puts it in perspective. AI is already improving how researchers prioritize biological targets, but the hardest part isn’t generating hypotheses. It’s proving that those hypotheses translate into patients.

5. IPO Tracker 2026

Looking through this year’s IPOs, one thing became obvious: capital is flowing back, but it’s flowing selectively. Most of the companies making it to market already have meaningful clinical data and experienced teams behind them.

The more interesting question isn’t whether the IPO window has reopened, it’s who still can’t get through it. Early-stage biotech is operating under very different financing conditions than late-stage companies, and that gap may shape innovation over the next few years.

6. Backed by top-tier VCs, stealthy biotech bags AlzeCure’s Alzheimer’s asset in $2.2B deal

My read on the structure alone: $12M upfront against $2.2B in milestones is a classic cash-runway rescue deal, not a signal that anyone has validated the asset. AlzeCure needed the cash; QuantumCell got a call option on an Alzheimer’s asset for almost nothing upfront.

7. Have people stopped trusting science? The data tell a surprising story

The data challenge a narrative we’ve all heard repeatedly: that public trust in science is collapsing. Across 68 countries, trust remains surprisingly high, with scientists still ranking above many other public institutions.

The nuance I found most interesting is that trust and influence aren’t necessarily the same thing. People may still trust scientists while spending more time consuming content optimized for engagement than for evidence. That distinction feels increasingly important for anyone thinking about science communication.

8. Two Stanford grads raise $11M for a noninvasive hormone-tracking wearable

Continuous hormone monitoring has the potential to become as transformative as continuous glucose monitoring but only if the measurements are actually reliable.

From what we know today, this company isn’t measuring hormones directly; it’s inferring them through physiological signals. That’s an important distinction. Founder pedigree and funding make for a compelling story, but biology ultimately doesn’t care about investor decks. Validation is the milestone that matters here.

9. Methionine-supplemented longevity diet increases GH, GLP-1, FGF21; reduces frailty

This paper is interesting because it challenges the simplistic idea that longevity is just about eating less protein. The authors argue that protein composition particularly methionine balance may matter just as much as total protein intake.

The mechanistic data in mice are compelling, but I’d be cautious about extrapolating too quickly. The human component is observational rather than interventional, which means we’re still a long way from translating these findings into dietary recommendations.

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Subscribe now

It’s become the default narrative.

The problem with default narratives is that they’re usually true, but not useful.

If you’re trying to understand where India’s wellness market is headed or whether it’s worth building for, the generic version of the story (”huge population, growing wallet, ancient wisdom”) doesn’t actually tell you much. The more interesting story is happening underneath those headlines.

India isn’t getting richer. Parts of India are.

Yes, disposable income is rising. [1]

But averages hide what’s actually happening.

The fastest growth in discretionary spending isn’t coming from India’s biggest metros. It’s increasingly coming from Tier-2 and Tier-3 cities, where consumers are spending more on premium categories while many international brands are still treating these markets as secondary. [2][3]

That’s a much more useful insight than saying “India is getting richer.”

At the same time, it’s important not to overstate the opportunity.

One of the biggest mistakes I see is brands talking about India’s 1.4 billion consumers. That’s not how premium wellness works.

Goldman Sachs estimates India’s affluent consumer base at roughly 60 million people in 2023, expected to grow to around 100 million by 2027. [4]

That’s still an enormous market. It’s just a much more realistic one. The opportunity isn’t “everyone.”

It’s a rapidly growing affluent consumer base that’s becoming more geographically distributed than ever before.

I don’t think “digital health literacy” is the right phrase.

Indian consumers are reading ingredient labels.

They’re searching for nutrition information.

They’re watching health creators.

The motivation to learn has never been higher. [5]

But access to information has grown much faster than people’s ability to evaluate it.

We often describe this as rising digital health literacy, but I think that’s the wrong framing.

Formal digital literacy remains uneven across the country, even as internet and smartphone adoption continue to rise. [6][7]

What we’re actually seeing is something more nuanced: consumers are actively trying to educate themselves in an information ecosystem where confidence often spreads faster than evidence.

That creates a fascinating customer.

They’re willing to spend time understanding ingredients, formulations and health claims.

They’re also surrounded by misinformation.

For wellness brands, that isn’t just a challenge.

It’s an opportunity.

The brands that invest in education and earn trust early will likely build far stronger customer relationships than those relying purely on marketing.

What makes India genuinely different

Indonesia has traditional medicine.

Brazil has traditional medicine.

Nigeria has traditional medicine.

So why does India feel different?

Because India isn’t just preserving traditional medicine.

It’s actively trying to build evidence around it.

The Ministry of AYUSH’s research bodies continue to run clinical studies on Ayurvedic interventions, while the WHO’s Global Traditional Medicine Centre is headquartered in Jamnagar, Gujarat. [8][9]

That combination is unusual.

India is one of the few places where traditional medicine, government support, regulatory infrastructure and clinical research are evolving together.

Whether every study succeeds isn’t really the point.

The fact that the infrastructure exists is.

The market is growing. The exact number matters less.

If you’ve ever looked up the size of India’s Ayurveda market, you’ve probably found five different reports giving five different answers.

That’s because everyone defines the category differently.

Personally, I don’t think debating whether the market is worth $12 billion or $18 billion changes much.

The consistent story across reports is that wellness and nutraceuticals in India continue to grow at sustained double-digit rates.

Grand View Research estimates India’s nutraceutical market at over $32 billion in 2024, with significant growth expected over the coming decade.[10]

That’s directionally the only number I think really matters.

What international brands keep getting wrong

Most global brands actually understand the macro story.

Where they struggle is execution.

First, they price for affluent consumers but distribute like they’re building for the mass market.

Second, they underestimate how long regulatory approvals can take, which quickly becomes a cash-flow problem.

Third, they import clinical claims from overseas instead of building trust locally through doctors, nutritionists and healthcare professionals.

And finally, many treat Ayurveda as branding rather than something that deserves scientific validation.

The brands that have lasted the longest haven’t positioned themselves as “traditional.”

They’ve positioned themselves as evidence-backed.

The strongest signal isn’t marketing.

It’s capital.

Two acquisitions announced within days of each other said more about India’s wellness market than any industry report.

USV, a pharmaceutical company with decades of credibility in prescription medicines, acquired a majority stake in Wellbeing Nutrition’s parent company to build what it described as a future-facing healthcare portfolio. [11]

At almost the same time, Hindustan Unilever completed its acquisition of OZiva after watching the company scale rapidly under its existing investment. [12]

Those are two very different businesses making essentially the same bet.

One comes from pharma.

The other from FMCG.

Both concluded that wellness in India is no longer an experiment.

It’s becoming infrastructure.

And I think that’s worth paying attention to.

Finally, this is why India is worth watching closely

India isn’t becoming one of the world’s most interesting wellness markets because incomes are rising or because people are spending more time on Instagram learning about health.

It’s becoming interesting because of a much stranger combination.

Spending power is growing fastest in places many global brands haven’t mapped yet.

Consumers are educating themselves faster than the information ecosystem can keep up.

And India is one of the few countries where traditional medicine and modern clinical research are evolving alongside one another.

That’s a much narrower claim than “India is the next big wellness market.”

But I also think it’s a far more useful one.

References

[1] Ministry of Statistics & Programme Implementation (MoSPI), Net National Income FY2024–25.

[2] Bain & Company, Festive Spending Insights 2025.

[3] World Economic Forum, India’s Consumer Spending Outlook (2026).

[4] Goldman Sachs Research, The Rise of India’s Affluent Consumer.

[5] Scoping Review of Food Labelling Research in India (2025).

[6] Ministry of Statistics, Comprehensive Annual Modular Survey.

[7] National Statistical Office, Digital Literacy Statistics.

[8] Ministry of AYUSH, Central Council for Research in Ayurvedic Sciences.

[9] WHO Global Traditional Medicine Centre.

[10] Grand View Research, India Nutraceutical Market.

[11] USV acquisition of Nutritionalab (Wellbeing Nutrition), February 2026.

[12] Hindustan Unilever acquisition of OZiva, February 2026

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

I’ve been paying close attention to the wearables space lately, especially how companies are leveraging biometric data to move beyond tracking and into more personalized health insights. There’s been a lot of activity, from new product launches to strategic partnerships and funding rounds.

A recurring theme across nearly every sector? AI. Whether in healthcare, biotech, or consumer health, AI continues to reshape how companies build, operate, and deliver value. It’s no longer a trend to watch from the sidelines, its becoming essential to understand and engage with.

Most of the major deals and developments have been concentrated in the U.S., but their implications will likely be felt globally.

Here’s a roundup of what caught my attention this month 👇📚

1. The Future of Wearables Is Interpretation, Not Data Collection

Whoop is moving beyond fitness tracking and into care navigation. Users will be able to connect with clinicians through the app while sharing months of biometric data collected from their wearable. The company is also integrating lab work, medical records, and health history to provide more contextual recommendations.

So what?

The wearable market is becoming increasingly commoditized. The real value is no longer in collecting data, it’s in interpreting it. Whoop is betting that consumers don’t just want more metrics; they want actionable answers. The interesting question is whether healthcare will eventually shift from episodic doctor visits to continuous monitoring platforms that sit between patients and providers.

2. Biotech Innovation Is Becoming Increasingly Borderless

This piece argues that restricting access to Chinese biotech may ultimately hurt American innovation. Chinese biotech has become a major source of novel drug candidates, and large pharmaceutical companies are increasingly licensing assets developed there. The author’s view is that innovation ecosystems benefit from competition and collaboration rather than isolation. The debate sits at the intersection of national security, industrial policy, and drug development economics.

So what?

Whether you agree with the conclusion or not, one thing is clear: biotech is no longer a purely national industry. Capital, talent, clinical trials, and intellectual property now move across borders. The future competitive advantage may not come from blocking foreign innovation, but from building ecosystems that can absorb and commercialize it faster.

3. South Asians continue to show elevated cardiovascular risk in the US

A longitudinal analysis comparing South Asian adults with other racial and ethnic groups in the United States found that South Asians had among the highest rates of prediabetes and hypertension by age 45. The study reinforces previous evidence that cardiometabolic risk emerges earlier in this population than many conventional screening guidelines assume.

So what?

This is another reminder that “average patient” medicine often misses high-risk populations. For founders and investors building in prevention, diagnostics, and chronic disease management, ethnicity-specific risk stratification is becoming increasingly important. One-size-fits-all healthcare remains a major blind spot.

4. The Next Frontier in Prenatal Nutrition May Be Ingredient Quality

A randomized controlled trial compared prenatal vitamins containing 6S-5-methyltetrahydrofolate (5-MTHF) with those containing folic acid. Researchers found that the 5-MTHF formulation reduced levels of unmetabolized folic acid while maintaining maternal and fetal folate status.

So what?

Most prenatal products compete on branding and ingredient lists. Studies like this suggest we may see greater emphasis on ingredient forms and bioavailability. The challenge will be determining when these biochemical differences translate into meaningful clinical outcomes rather than simply marketing claims.

5. Great Science Does Not Automatically Build Great Companies

A useful reminder that great science is not the same thing as a great company. Publishing in prestigious journals can validate a scientific hypothesis, but it doesn’t solve manufacturing challenges, reimbursement hurdles, regulatory risk, or market adoption.

So what?

The biotech industry still tends to over-index on scientific novelty. Investors and founders often underestimate how much value creation happens after the paper is published. Translational execution, not discovery alone, is where many companies succeed or fail.

6. Healthcare Incentives Often Matter More Than Healthcare Technology

The article breaks down the incentives, stakeholders, and structural complexities that make US healthcare simultaneously innovative and expensive.

So what?

Many healthcare startups focus on solving a clinical problem. The companies that scale typically solve an incentive problem. Understanding who pays, who benefits, and who makes decisions often matters as much as understanding the disease itself.

7. Data May Become More Valuable Than AI Models

A curated list of biotech companies leveraging AI across drug discovery, biology platforms, and therapeutic development.

So what?

The AI conversation in biotech is gradually shifting from “who uses AI” to “who generates proprietary biological data.” Models can increasingly be replicated. Unique datasets, experimental infrastructure, and feedback loops are becoming the more defensible assets.

8. We're Still Waiting for Biology's Foundation Model

This piece explores the idea that biology still lacks a true foundation model equivalent to what large language models became for text.

So what?

Biology remains fundamentally different from language. Biological systems are noisy, incomplete, and governed by complex physical constraints. The winner in AI-biology may not be the company with the largest model, but the one that best integrates computation with real-world experimentation.

9. How well can your wearable track sleep?

The article reviews research around wearable sleep tracking and highlights the strengths and limitations of current devices.

So what?

Wearables are getting better at identifying trends, but they’re still imperfect diagnostic tools. The more interesting use case may not be measuring sleep with clinical precision, but helping users understand behavioral patterns over time and prompting healthier decisions.

10. Big Pharma Is Looking East for Innovation

Pfizer signed a collaboration worth up to $10.5 billion with Chinese biotech company Innovent to develop 12 oncology programs. The agreement includes a $650 million upfront payment and further milestone payments tied to development and commercialization.

So what?

This deal is another data point showing that China has evolved from being viewed primarily as a manufacturing hub to becoming a source of innovative drug assets. For global biotech, the center of gravity is becoming more distributed than many expected a decade ago.

11. The Hardest Part of Innovation Is Usually Adoption (AgTech Version)

The argument here is that agriculture doesn’t necessarily suffer from a lack of innovation. Instead, the challenge lies in moving technologies from the lab into real-world farming environments where adoption, distribution, and economics become critical.

So what?

This theme extends far beyond agriculture. Across biotech, health tech, climate tech, and food systems, the bottleneck is increasingly translation rather than invention. We have more technologies than ever. The challenge is deploying them at scale, economically and reliably.

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Subscribe now

Read:

Your Local Epidemiologist

Peptides, explained: Answers to your top questions

Peptides. are. everywhere. Someone is injecting themselves with a small vial before a workout. A wellness clinic advertises “regenerative peptide therapy.” A podcast host credits a peptide with healing his tendon in two weeks. Google Trends shows searches for “peptides” taking off like a rocket this year…

Read more

4 months ago · 450 likes · 28 comments · Katelyn Jetelina

This piece breaks peptides down with far more nuance than the wellness internet typically offers. Peptides are short chains of amino acids, but grouping them together as one “health trend” is misleading. Some, like insulin or GLP-1s, are clinically validated therapeutics; others are marketed aggressively despite limited human data.

The article’s biggest contribution is separating medically proven peptides from gray-market compounds, especially as consumer demand surges around anti-aging, weight loss, and performance optimization.

Key insight:

Peptides may represent the next major category where consumer health enthusiasm outpaces regulatory and scientific literacy.

2. India’s biotech challenge isn’t talent, it’s structural capital

Read: https://www.moneycontrol.com/news/business/kiran-mazumdar-shaw-calls-for-new-ipo-rules-to-unlock-india-s-innovation-potential-in-life-sciences-13882059.html

Mazumdar-Shaw argues India’s requirement for revenue track records before IPO eligibility is fundamentally misaligned with biotech, where companies often spend years in R&D before commercialization. Her broader thesis: India doesn’t lack scientific capability—it lacks financial pathways designed for life sciences innovation.

Key insight:

Without pre-revenue biotech capital structures, India risks staying a manufacturing powerhouse rather than becoming a frontier biotech ecosystem.

3. AI is changing who gets to participate in biomedical problem-solving

Read:

This piece centers around a deeply personal mission: using AI tools, biomedical research, and open scientific systems to better understand and potentially impact treatment pathways for a loved one’s brain tumor.

The broader implication is powerful: AI is lowering barriers to information access, hypothesis generation, and scientific participation.

Key insight:

Biotech may increasingly shift from institution-only participation to AI-augmented independent agency.

Subscribe now

4. Eroom’s Law still looms over biotech but discovery efficiency matters differently for startups

Read:

The Century of Biology

AI Versus Eroom's Law

Welcome to The Century of Biology! This newsletter explores data, companies, and ideas from the frontier of biology. You can subscribe for free to have the next post delivered to your inbox…

Read more

5 months ago · 75 likes · 5 comments · Elliot Hershberg

One of my favorite substack talks about why biotech innovation remains economically difficult despite technological advances. While large pharma is burdened by clinical and commercialization costs, startups are often constrained by discovery quality, translational success, and early-stage target validation.

Key insight:

AI’s biggest value may not simply be faster discovery, it may be improving probability-adjusted biology and making early-stage biotech more viable.

5. Frontier founders are increasingly building infrastructure, not just products

Read:

Venture Curator

What are the smartest founders building right now (according to YC)? | The biggest gap in AI right now? 40% of companies can’t measure ROI.

👋 Hey, Sahil here - Welcome back to Venture Curator, where we explore how top investors think, how real founders build, and the strategies shaping tomorrow’s companies…

Read more

4 months ago · 44 likes · Sahil S

This article argues that the smartest founders are increasingly focused on infrastructure: observability, orchestration, trust layers, workflow optimization, and enterprise systems rather than just visible consumer-facing products.

Key insight:

In frontier sectors, infrastructure often becomes the hidden value layer.

6. Semaglutide may be reshaping more than weight, it could alter alcohol consumption behavior

Read:

ON THE PEN

Semaglutide and Alcohol: A New Study in The Lancet is Worthy of Attention

There’s a particular kind of exhaustion that comes with alcohol use disorder. Not just the physical kind, though that’s real too. I’m talking the kind that settles into your bones after years of trying, having minimal success, and trying again. After being told, in ways spoken and unspoken, that the problem was really just a lack of willpower. That if y…

Read more

4 months ago · 13 likes · 2 comments · On The Pen GLP-1 News

This piece explores emerging evidence and growing public interest around semaglutide’s potential effects beyond weight loss—particularly its possible role in reducing alcohol cravings or changing drinking behavior. The article examines how GLP-1 receptor agonists, originally designed for metabolic conditions, may influence reward pathways tied to addiction and compulsive behaviors.

While the science is still developing, the broader implication is significant: a blockbuster obesity drug class may also intersect with behavioral health categories like alcohol use disorder, opening questions around new therapeutic markets, off-label curiosity, and how metabolic drugs may influence broader lifestyle patterns.

Key insight:

Semaglutide may represent a larger pharmaceutical shift where metabolic therapies begin crossing into behavioral and addiction-related health outcomes, potentially redefining how one drug class impacts multiple public health challenges.

7. Longevity is expanding fast but the movement may be drifting from science into excess

Read:

Dr. Inigo San Millan

Longevity Field Is Getting Out of Hand

Every few months, a new therapy arrives with the same promise: activate this pathway, inhibit that enzyme, filter your blood, flood your cells with light, and the clock of aging will slow. NAD+ precursors, senolytics, mTOR inhibitors, plasmapheresis, ozone infusions, methylene blue. The list grows longer, the marketing grows louder, and the evidence, th…

Read more

4 months ago · 153 likes · 23 comments · Dr. Inigo San Millan

This piece examines how the modern longevity movement, once centered on extending healthspan through credible science is increasingly at risk of spiraling into hype, optimization obsession, and commercial overreach. As more founders, influencers, and consumers chase biomarkers, supplements, and extreme protocols, longevity can start to shift from evidence-based prevention toward a culture of endless intervention.

The article raises a core tension: while advances in aging science are real, the market surrounding longevity is growing faster than consensus around what meaningfully improves long-term health. The result is a space where aspiration, fear of aging, and commercialization can blur scientific rigor.

Key insight:

Longevity may remain one of healthcare’s biggest opportunities but without stronger scientific grounding, it risks becoming a sector where optimization culture outpaces actual evidence.

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

The core idea: You don’t need to be the best scientist to be the most valuable person in the room. You need to understand the science and translate it into decisions, dollars, or policy. That person is rare. This guide helps you build toward being that person.

Four roles are in particularly high demand right now for exactly this reason:

• BD and partnerships (science background + commercial sense)

• Regulatory strategy (scientific + legal + strategic thinking)

• Science communication and content

• Clinical operations with startup sensibility

Each one requires someone who can hold two mental models at once. This guide is about building that capacity.

Subscribe now

The 6 core bridge skills

These skills are learnable without another degree.

They compound.

And they’re visible; you can build proof of each one publicly.

SKILL 01

Scientific literacy without the PhD gatekeeping

Read a paper in 20 minutes. Know what matters, what’s noise, and what questions to ask. You don’t need to reproduce the experiment, you need to know if the conclusion is supported.

USE CASE

A BD analyst who can evaluate a licensing deal’s scientific rationale, not just the financials. That’s who gets in the room.

START HERE

Practice reading abstracts + discussion sections. Summarise each in 3 bullets for a non-scientist.

SKILL 02

Business and financial basics

Market sizing, unit economics, ROI framing, and how deals get structured in pharma and biotech. You don’t need to build a DCF model, you need to understand what drives value in a deal.

USE CASE

Explaining to a CFO why a Phase 2 failure isn’t a write-off, the IP still has partnering value. That reframe is worth millions.

START HERE

Learn what NPV, milestone payments, and royalty tiers mean in a licensing deal. Read a few publicly available deal announcements and reverse-engineer the logic.

SKILL 03

Regulatory awareness

Know the FDA and EMA approval landscape. Understand IND, NDA, 510k, and when each matters. Not as a compliance function but as a strategic lens.

USE CASE

A startup raising a Series A. The investor asks about the regulatory pathway. You can answer clearly and confidently. That’s a signal of credibility that most scientists can’t send.

START HERE

Read 2–3 FDA approval press releases and trace the product back through its trial history on ClinicalTrials.gov.

SKILL 04

Communication and storytelling

Write for scientists. Write for investors. Write for patients. Three completely different registers but it’s one skill: knowing your audience well enough to change what you emphasize.

USE CASE

A clinical comms brief that helps a trial site explain informed consent to a first-generation patient. This isn’t dumbing down, it’s precision in the opposite direction.

START HERE

Take one study you know well. Write a 200-word explainer for a 16-year-old, then rewrite it for a VC. Notice what you changed and why.

SKILL 05

Data literacy

Not coding but understanding p-values, endpoints, trial design, and when a graph is being used to mislead. This is the skill that makes you hard to fool.

USE CASE

Spotting a surrogate endpoint used in a trial where overall survival data wasn’t yet mature and flagging the risk to leadership before they quote the data to investors.

START HERE

Learn the difference between primary and secondary endpoints, and what a hazard ratio actually says. Read STAT News regularly, they explain trial results in plain language.

SKILL 06

Cross-functional navigation

Know how to get things done across R&D, medical affairs, legal, and commercial teams. Understand what each function cares about — and use that to move things forward.

USE CASE

A regulatory submission delayed because medical affairs and legal are misaligned on label language. You can broker that conversation because you understand both sides.

START HERE

Shadow or have an informational interview with someone in a different function. Map how their work connects to yours on a single page.

The 4 bridge career tracks

Track 01 · Science + Commercial

🤝 BD and partnerships

You are the translator between what the science can do and what the market will pay for. You evaluate deals, build partnerships, and help companies decide what to in-license, out-license, or acquire.

Day-to-day reality: Reading data packages, building relationship maps with potential partners, sitting in deal negotiation prep, writing term sheet summaries that the CEO can act on in 10 minutes.

Skills

1. Scientific literacy

2. Financial basics

3. CRM & outreach

4. Negotiation

5. Competitive landscape

Track 02 · Science + Legal + Strategy

⚖️ Regulatory strategy

You sit at one of the most complex intersections in the industry, helping companies design development programmes that will actually get approved.

Day-to-day reality: Reviewing FDA guidance documents, preparing for Type B meetings, advising on label strategy, and working with clinical teams to design trials regulators will accept.

Skills

1. FDA/EMA pathways

2. Clinical trial design

3. Legal reading

4. Document writing

5. Risk framing

Track 03 · Science + Editorial craft

✍️ Science communication and content

Science that no one understands doesn’t save lives. Whether it’s patient education, investor decks, medical content, or public policy, someone has to make it legible. That someone is increasingly valuable.

Day-to-day reality: Writing explainers for new therapies, creating congress materials, building educational content for HCPs, running a company’s science-facing LinkedIn presence.

Skills

1. Writing for audiences

2. Medical accuracy

3. Visual storytelling

4. SEO/content basics

5. Social platforms

Track 04 · Execution + Startup agility

🚀 Clinical operations (startup mode)

Biotech startups run trials with skeleton crews. Someone needs to manage sites, vendors, timelines, and budgets while understanding the science well enough to know when something is off.

Day-to-day reality: Managing CRO relationships, tracking patient enrollment, writing SOPs from scratch, flagging protocol deviations, and presenting trial status to a CEO who’s also wearing five other hats.

Skills

1. GCP basics

2. Project management

3. Vendor negotiation

4. Protocol literacy

5. Startup agility

Where to start building

1. Pick one science topic you already know well.Use it as your translation sandbox. Write one explainer for a non-scientist. Then write a one-pager on its commercial opportunity. Build the muscle on familiar ground.

2. Read widely across the industry. STAT News, Endpoints News, FiercePharma, FDA press releases. Not for depth, for pattern recognition. You’ll start noticing how science, money, and regulation connect.

3. Find one person already doing this work. BD analyst, regulatory consultant, science writer at a biotech startup. Ask for 20 minutes. Ask: what do you read, what skills gap did you have to fill, what would you tell your younger self?

4. Create visible proof of the bridge. A LinkedIn post explaining a recent drug approval. A mock deal memo. A regulatory timeline you mapped yourself. The goal is a portfolio that says: this person thinks in both worlds.

5. Go get a role with deliberate breadth. Small biotech, consulting, a startup in clinical. Places where your job title doesn’t cage you. The intersection becomes your identity when you’ve lived in it, not just studied it.

Resource list

Daily reads and newsletters

STAT News (free) statnews.com — Gold standard for life sciences news. Covers science, business, and policy in the same publication — exactly the intersection you’re building toward.

Endpoints News (free tier) endpts.com — Biotech-focused daily. Great for tracking deals, trials, and regulatory decisions. Understand what’s moving the industry week to week.

FierceBiotech / FiercePharma (free) fiercebiotech.com — Quick, digestible news bites on deals, approvals, and clinical results. Good for staying current without drowning in detail.

FDA Press Releases (free) fda.gov — Every approval, rejection, and guidance update. Reading these weekly gives you a regulatory radar no course can teach.

The Readout LOUD (Endpoints Podcast) (free) endpts.com/podcast — 30-minute daily biotech podcast. Conversations with founders, BD leads, and operators. Perfect for commutes or gym time.

Nature News & Comment (free) nature.com/news — High-quality science journalism. Trains you to explain why a result matters, not just what it found.

Courses and certifications

Clinical Trials Design Specialisation — Johns Hopkins via Coursera free to audit coursera.org — Covers endpoints, randomisation, blinding, and statistical design. The clinical literacy foundation every bridge person needs.

CDER Learn — FDA (free) fda.gov/cder-learn — Official FDA training on drug development, review processes, and regulatory submissions. Primary source, completely free.

GCP Certification (ICH E6) often (free) The Good Clinical Practice certification required for most clinical research roles. Often available for free through university or institutional portals. Get this early.

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

On one hand, it is the pharmacy of the world, supplying roughly 20% of global generics by volume. On the other hand, it sits on one of the richest repositories of medicinal biodiversity and traditional knowledge on earth.

And still, India’s big moment in plant-based, innovation-driven pharmaceuticals remains a dream.

The Opportunity: A Sleeping Giant in Separate Rooms

India’s strength in phytopharmaceuticals is, on paper, undeniable. It holds thousands of documented plant species with therapeutic potential, a millennia-old Ayurvedic tradition and a generics industry that has already proven it can manufacture and distribute medicine at global scale.

The global market validates this opportunity in herbal and plant-based therapeutics.

This is not a niche. It is a mainstream and rapidly growing segment of global healthcare. India, as one of the richest biodiversities, should be at the centre of it.

Not because the plants are not there. Not because the science is not there. But because the opportunity sits scattered across four unconnected domains that have never been asked to work together:

• Traditional and tribal knowledge: held in communities, largely oral, largely undocumented in any scientifically usable form.

• Codified Ayurvedic knowledge: catalogued in the TKDL and classical texts, protected from foreign misappropriation but disconnected from modern drug discovery pipelines.

• Academic and institutional science: generated in CSIR labs, university ethnobotany departments and AYUSH research bodies, but rarely translated into commercial drug candidates.

• Regulatory and commercial infrastructure: a generics industry and a 2015 drug approval framework, built for different purposes, not yet oriented toward plant-based innovation.

Recognising this, India took a critical step in 2015, introducing a distinct regulatory category for phytopharmaceuticals under the Drugs and Cosmetics Rules. Unlike many regulatory systems that classify herbal products merely as supplements, India created a pathway to treat them as scientifically validated drugs. Institutional support followed with increasing R&D focus on medicinal plants.

On paper, this should have catalyzed a wave of innovation. Reality tells a different story.

Subscribe now

The First Crack: When a System Cannot Define Itself

Before a product can be developed, funded, approved or exported, it has to be defined. And India, uniquely, has given itself two incompatible answers to the question: what is a phytopharmaceutical?

India’s regulatory definition under CDSCO is precise and demanding: a phytopharmaceutical drug is a purified and standardised fraction of a plant extract, containing a minimum of four defined and characterised bioactive or phytochemical compounds (qualitatively and quantitatively assessed), supported by preclinical and clinical trial data, for internal or external use, but explicitly excluding administration by parenteral route.

This is a synthetic drug-level bar applied to a plant-derived product.

On the other side sits AYUSH, the Ministry of Ayurveda, Yoga, Naturopathy, Unani, Siddha and Homoeopathy, which regulates herbal products under a framework grounded in traditional knowledge systems. Efficacy is established through classical texts and historical use. The bar for market entry is accessibility-oriented, not clinical-evidence-oriented.

Two ministries. The same plant. Two completely different standards. And no formal translation pathway between them.

This is not a gap. It is a contradiction built into India’s own system. Companies must choose between a hard, expensive CDSCO pathway with no approved products to learn from, and an easier AYUSH route with years of precedent behind it. Most choose AYUSH. The rigorous pathway sits largely unused while the permissive one fills with products that will never reach global markets.

The TKDL Paradox: A Policy Gap Inside a Definitional Gap

The fragmentation goes even deeper, into the knowledge layer itself. India’s Traditional Knowledge Digital Library, established in 2001, has documented over 80,000 Ayurvedic formulations and successfully challenged 300+ patent applications at global patent offices. As a tool to stop foreign biopiracy, it is world-class.

But it was never built for drug discovery. It records plant names and classical preparation methods, not the chemical identities of active compounds. A researcher cannot search it by pharmacological target or molecular structure. India’s own knowledge is protected from foreign hands but locked away from its own scientists.

Access was widened to researchers and industry in 2022 ,twenty-one years after the database was created. And even now, the chemical data that modern drug development requires is not there.

The Missing Middle: Why India Has No Globally Approved Phyto Drugs

01) We mastered generics, not discovery: India’s pharma success has historically been built on process innovation, not new drug discovery. Phytopharmaceuticals require target identification, bioactive isolation, and clinical validation, a completely different capability stack.

02) Standardisation is a scientific nightmare: Plants, unlike single-molecule drugs, vary in composition with geography, climate and cultivation. This creates batch-to-batch inconsistency and reproducibility problems that slow development pipelines drastically.

03) Clinical trial burden is high: Unlike traditional medicines, phytopharmaceuticals typically undergo preclinical studies, Phase I–III clinical trials and post-marketing surveillance. This makes them as expensive and time-consuming as synthetic drug development but, without the same investor confidence.

04) Weak academic to industry translation: India has world-class plant science in CSIR labs, university departments, AYUSH research bodies. But there is no real bridge between a published research paper and a drug that can be filed with CDSCO. Science exists. The path from science to product does not.

05) No one has gone first: India’s biotech sector grew from USD 10 billion in 2015 to USD 165 billion in 2024. Phytopharmaceuticals saw almost none of it, not because investors are irrational, but because no drug has ever completed the full CDSCO pathway.

No product → no confidence → no funding → no product.

One approved phyto drug would break this cycle faster than any government scheme. That first example is what the entire ecosystem is waiting for.

One successful CDSCO approval - A single plant-derived drug completing the full phytopharmaceutical pathway would do more for investor confidence than any policy paper. The first proof of concept is the missing keystone.

We also carry a perception problem. ‘Herbal’ is considered safe but not scientifically rigorous. ‘Pharmaceutical’ is considered effective but synthetic. Phytopharmaceuticals sit uncomfortably between; trusted by neither group fully.

The End Game: Evolving Regulation, Incomplete Execution

India’s regulatory framework is progressive but incomplete. Treating phytopharmaceuticals as new drugs ,demanding quality, safety, and efficacy data aligns with global regulatory standards. But the guidelines are still evolving. There are no clearly defined fast-track pathways. There are no targeted financial incentives for industry.

The intent is strong. The execution is still catching up. India does not lack plants, knowledge, scientists or market demand. It lacks alignment across the value chain.

What India Can Do: Clear, Actionable Levers

01) Define ‘Natural Product’ strategically: Create a tiered classification system: Traditional herbal → Standardised extracts → Fully validated Phytopharmaceuticals. This reduces ambiguity, streamlines fragmented classifications into a coherent translational pathway, and guides industry toward the right track.

02) Build a middle pathway: Not every phyto drug requires rigorous Phase III trials. Adaptive regulatory pathways, conditional approvals, and real-world evidence frameworks can meaningfully accelerate the process.

03) Invest in standardisation infrastructure: National platforms for phytochemical profiling, reference standards, and controlled cultivation should be established. This directly addresses the reproducibility bottleneck that currently kills pipelines.

04) Incentivise industry risk-taking: Grants for plant-based drug discovery, public-private partnerships, and tax incentives for phytopharma R&D can shift the risk calculus. One anchor approval ,publicly documented and ideally licensed internationally would break the funding doom loop faster than any incentive scheme alone.

05) Build the translation corridor: The route between AYUSH and modern pharma must either be marked clearly or a formal translation pipeline must be created, so a traditional formulation can become a validated phyto drug without institutional confusion or regulatory arbitrage.

India has already won the generic drug race. The next frontier is not replication, it is discovery and innovation.

Hidden in forests, manuscripts and molecules yet to be isolated lies a different kind of pharmaceutical revolution. The knowledge is there. The biodiversity is there. The market is there. The science is there.

The question is not whether India has the plants, the science or the market. The question is whether India can finally build the corridors between the rooms it has already furnished.

References:

1. Learnings from the ToNPR conference (National Conference on Translational Opportunities in Natural Products Research), 2026 at CSIR-IICT, Hyderabad.

2. Bhatt A. Phytopharmaceuticals: A new drug class regulated in India. Perspect Clin Res. 2016 Apr-Jun;7(2):59-61. doi: 10.4103/2229-3485.179435. PMID: 27141470; PMCID: PMC4840792

3. General Guidance for Development of Phytopharmaceutical Drugs

4. Phytopharmaceuticals - Immense Potential in India

5. CSIR - Phytopharmaceuticals Mission

Written by

Hiya Aidasani is a Master’s student at IIT Hyderabad with a strong interest in the intersection of science, business, and strategy. She is fascinated by how biological breakthroughs evolve into real-world therapeutics, diagnostics, medtech and biopharma solutions that shape modern healthcare. She is particularly drawn to building and scaling ideas in the life sciences space, and communicating complex scientific concepts in ways that make them more accessible and impactful.

Contributions by: Prushti Shah

From oncology deals to GLP-1 geopolitics and AI-driven drug discovery—recent signals point to a single trend: biology is becoming more programmable, more scalable, and far more commercial.

1. Big Pharma continues to shop for oncology innovation

Novartis Acquires Next-Generation Breast Cancer Drug in $3 Billion Deal

Novartis is doubling down on oncology with another multi-billion-dollar acquisition, reinforcing a familiar pattern: large pharma prefers to buy late-stage assets rather than build them internally. This deal underscores how breast cancer remains one of the most commercially strategic therapeutic areas, especially as precision oncology continues to segment patient populations into increasingly niche but lucrative subgroups.

The broader takeaway: innovation is happening in smaller biotech pipelines, but value is still being captured at the Big Pharma consolidation layer.

Subscribe now

2. AI drug discovery finally enters women’s health at scale

Insilico Medicine and ASKA Pharmaceutical Partner to Discover Novel Drug Targets for Endometriosis, Fibroids and Adenomyosis

Women’s health has historically suffered from underfunded research and limited mechanistic understanding. This collaboration is notable because it applies AI-driven target discovery to three of the most complex gynecological conditions, areas where biology is poorly mapped and clinical endpoints are messy.

If successful, this could mark a shift where AI doesn’t just accelerate existing pipelines but actually unlocks entirely new therapeutic categories in femtech.

3. India’s GLP-1 moment: from access gap to manufacturing hub

India’s Race to Manufacture Affordable Obesity Drugs Amid Ozempic’s Market Entry

With semaglutide patents loosening and demand exploding, Indian pharma is positioning itself to dominate the global generics supply chain for obesity drugs. The opportunity isn’t just domestic, India is eyeing exports to cost-sensitive markets where branded GLP-1s remain out of reach.

This is less about obesity and more about India’s long-standing competitive advantage: scaling complex small-molecule manufacturing faster and cheaper than Western peers.

4. HIV treatment quietly evolves toward simpler daily regimens

Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data

The HIV treatment landscape is already dominated by long-acting injectables and combination therapies, so it’s easy to overlook incremental improvements. But daily oral regimens that improve adherence without sacrificing efficacy remain crucial especially in lower-resource settings where cold-chain and clinic access still limit injectable rollout.

This is a reminder that in global health, “good enough but scalable” often beats “best-in-class but complex.”

5. The oral GLP-1 race heats up and Lilly pulls ahead

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

Eli Lilly’s orforglipron, a small-molecule oral GLP-1, demonstrated superior glycemic control and weight loss compared to Novo Nordisk’s oral semaglutide in a head-to-head Phase 3 trial. The significance isn’t just clinical, it’s logistical. A room-temperature-stable, injection-free GLP-1 could massively expand access and payer acceptance.

This could reshape the economics of the entire obesity category, turning what is currently a biologics-driven market into one that behaves more like traditional small-molecule pharma.

6. Biosecurity is entering its “AI moment”

Reasons to be pessimistic (and optimistic) on the future of biosecurity

As AI tools become capable of designing proteins, metabolic pathways, and even experimental protocols, biosecurity is shifting from a lab-containment problem to an information-access problem. The article outlines a dual reality: biotechnology is becoming more democratized, but governance frameworks are lagging behind the pace of innovation.

This tension between openness and safety will define the next decade of synthetic biology policy.

7. “Physical AI” in agriculture: rebranding or real shift?

‘Physical AI’ in Agriculture: Real Technical Shift or Just a New Label for Ag Robotics?

There’s a growing narrative that robotics plus machine learning equals a new category called “physical AI.” In agriculture, this includes autonomous tractors, AI-guided crop monitoring, and robotic harvesting. The article argues that while the terminology may be hype-driven, the integration of perception, planning, and actuation is materially changing how farms operate—especially in labor-constrained regions.

In other words, the branding may be new, but the productivity gains are real.

8. The overlooked downside of GLP-1 adoption: micronutrient health

The GLP-1 Iron Paradox: India’s Next Public Health Challenge

As GLP-1 drugs reduce appetite and caloric intake, they may inadvertently worsen micronutrient deficiencies, particularly iron, in populations where baseline nutrition is already fragile. In India, where anemia is endemic, this could create a paradox: metabolic health improves while nutritional health deteriorates.

It’s a reminder that pharmacological solutions rarely operate in isolation from broader public health realities.

9. Four molecules that could define industrial biotech’s next decade

The Four Molecules To Scale For Industrial Biotech

This piece highlights a pragmatic perspective often missing in synthetic biology discourse: not every engineered pathway needs to become a startup. Instead, the industry may consolidate around a handful of high-volume, high-margin molecules where fermentation and biomanufacturing can actually beat petrochemical incumbents.

Industrial biotech’s success will likely be determined less by scientific possibility and more by feedstock economics, downstream processing costs, and global commodity markets.

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

It is the investment arm of the Novo Nordisk Foundation and one of the largest dedicated pools of life sciences capital in the world, managing more than €142 billion (~₹13.5 lakh crore).

That structure matters when reading their India investments.

Most global investors in Indian healthcare operate with diversified portfolios. Firms like TPG or Temasek back hospital chains or diagnostics businesses alongside dozens of investments across technology, infrastructure and consumer sectors.

Novo operates differently.

Healthcare is not just one vertical among many. It is their driving mandate. Their capital is evergreen, backed by a foundation rather than limited partners. There are no fund lifecycles, no pressure to exit within 5-7 years. That allows them to invest against structural healthcare shifts that may take a decade to fully play out.

And recently, they have been leaning harder into India.

Their Asia head, Amit Kakar, has noted that the firm’s average India deal size has grown from roughly $20–30 million (~₹184–276 crore) to $50–125 million (~₹460–1,150 crore). They opened a Mumbai office in 2025 and placed partners on the boards of recent investments.

This is not exploratory capital. It looks like the early stages of a thesis being built.

Eight bets and one very deliberate absence

Since 2022, Novo has backed eight companies across the Indian healthcare ecosystem.

Hospitals, genomics, AI diagnostics, insurance administration, med-tech packaging and food quality technology. Every one of them serves the Indian market directly.

Now notice what is missing.

No generic drug manufacturers. No CDMOs. No API producers. Not a single export-oriented pharma company.

In a country whose global healthcare reputation was built on pharmaceutical exports, that absence stands out.

My read is that Novo’s India portfolio reflects a structural conviction: the next decade of value in Indian healthcare will come from organising domestic demand, not expanding the export supply chain.

The pattern across their investments starts to make sense when viewed through that lens.

Reading Novo Holdings’ India Portfolio: Four Signals

01 Every bet is domestic facing

Manipal, Medanta and Surya treat Indian patients. MedGenome sequences Indian genomes and runs South Asia’s largest genetic testing network. Qure.ai deploys AI imaging at Indian hospitals and government health programmes. Medi Assist administers health benefits for Indian insurance policyholders. There is no export revenue dependency anywhere in the portfolio. Every rupee of value created serves India’s own healthcare system.

This matters because the domestic side of Indian healthcare is moving in ways that are hard to ignore. Health expenditure grew at an 18% CAGR over the last four years, reaching INR 6.1 lakh crore (~$66 billion) in 2024-25. Health insurance penetration remains below 25% of the population. The single specialty hospital segment alone is projected to grow from $16 billion (~₹1.47 lakh crore) today to $40 billion (~₹3.68 lakh crore) by 2032. Novo’s portfolio is positioned squarely inside that growth curve, not outside it.

02 All growth stage. No early biotech.

Every company Novo has backed in India has already proven its model and needs capital to scale. There is no early-stage Indian biotech here, no drug discovery, no science coming out of an Indian lab. Novo backs early-stage science in the US, Europe and China. The fact that they do not in India yet suggests they trust Indian execution but are not yet willing to bet on Indian scientific innovation. That gap says something important about where the ecosystem stands.

It also reflects where the Indian healthcare ecosystem actually is. The infrastructure for translational science, early-stage funding pipelines and deep biotech commercialisation is still maturing. Novo appears to be reading that maturity curve accurately, backing what India does well right now and staying patient on the rest.

03 Zero pharma manufacturing exposure, intentionally

Across eight investments, Novo has not touched generic drug manufacturing, API production or traditional CDMOs. The one manufacturing-adjacent bet, SCHOTT Poonawalla, is injectable packaging for high-value biologics, not commodity generics. Even where they approach manufacturing they are at the premium, high-complexity end. The broad export pharma story has been skipped entirely. That is not an oversight in a portfolio this deliberate.

The context makes that absence sharper. Generic drug prices in the US have faced persistent erosion in mature categories. CDMO margins are under pressure as more players compete for the same mandates. The China-plus-one opportunity is real but finite and increasingly crowded. The tailwinds that defined Indian pharma exports for three decades are harder to ride. Novo, it seems, has priced that in.

04 B2B infrastructure throughout, no consumer health exposure

MedGenome and Qure.ai look like health tech but both are institutional businesses selling to hospitals, clinicians and governments. There is zero B2C exposure in this portfolio: no wearables, no wellness subscriptions, no D2C diagnostics. Consumer health in India still has a trust and unit economics problem to solve. Novo appears to have decided to build the infrastructure layer and wait for consumer behaviour to catch up.

Other serious investors have noticed the domestic opportunity as well. TPG went deeper into Manipal after Novo came in, and Temasek has been active across hospital groups and diagnostics. But most still carry export exposure alongside domestic positions. Novo carries none. The portfolio reads like a clean, committed thesis built by an investor with the structure to act on conviction before it becomes consensus.

Portfolio construction often reveals an investor’s thesis more clearly than public statements. Novo Holdings’ India portfolio offers four signals about how global life sciences capital may be reading the country’s healthcare opportunity.

References

1. Novo Holdings invests in Surya Hospitals — January 2026

2. Novo Holdings investments overview

3. Reuters — Novo Holdings India deal size escalation, Amit Kakar interview

4. India National Health Accounts — Ministry of Health and Family Welfare

5. MedGenome — South Asia’s largest genomics platform

6. Qure.ai — AI diagnostics and FDA clearance announcements

7. India health insurance market forecast 2024-2030

8. Single specialty hospitals India market — $40B projection by 2032

Written by

Sheshank Singh is a recent Economics graduate from King's College London with a background in Health Economics and Outcomes Research in the EMEA region. He is interested in healthcare capital markets and investment trends in India, particularly in analysing how global capital allocates across emerging healthcare ecosystems.

Contributions by Akash Parvatikar & Hiya Aidasani

Happy almost march! My reads this past two weeks were pretty versatile: AI-native biology, women-focused health models, food regulation shifts, pharma disruption, and India positioning biotech as a national growth engine.

Here’s what stood out.

🧠 AI Is Becoming Core Infrastructure in Biology

Introducing Episteme: A New System for Science
A bold attempt to rethink how scientific knowledge is structured, synthesized, and built upon. The idea isn’t just better papers - it’s better epistemology. If science is slow, maybe the problem is structural.

On AI Infrastructure in Biology
This piece argues that biology’s bottleneck isn’t models - it’s infrastructure. Data layers, tooling, reproducibility, and shared computational systems will define who wins in AI-biology.

Scaling Bio: Formation Bio’s CTO on Building an AI-Native Pharma
A fascinating look inside Formation Bio and what it means to build pharma from the ground up with AI embedded in operations. My takeaway: AI-native pharma won’t just optimize pipelines, it will redesign them.

🌸 Women’s Health Is Finally AI-First

Oura launches a proprietary AI model focused on women’s health
This is bigger than a feature update. It signals that women’s health is no longer an afterthought in wearables; it’s becoming model-trained, data-specific, and intentionally built.

We’re moving from “cycle tracking” to “biologically informed personalization.”

🩺 Rethinking Medical Care

“I’m a doctor. Here’s what opened my mind about the future of medical care.”
A physician reflecting on AI, chatbots, and how clinical care may evolve. What I appreciated: this wasn’t hype. It was a nuanced shift from skepticism to cautious optimism.

Healthcare change won’t be flashy. It’ll be gradual and operational.

🇮🇳 India’s Bioeconomy Ambition

India targets $1 trillion bioeconomy by 2047
India is publicly positioning biotechnology as a pillar of its economic future. That framing matters. When governments anchor biotech to industrial policy, ecosystems accelerate.

💰 Capital & Disruption Signals

Deepinder Goyal’s Temple raises $54M
A health-tech play backed by serious capital. India’s consumer-tech founders entering healthcare is a trend worth watching.

Mecha Health raises $41M to build foundation models for radiology
Radiology remains ground zero for applied AI in medicine. Foundation models suggest the category is maturing beyond narrow use cases.

US FDA clears spirulina-based blue colors for wider use in food
Regulatory shifts in food ingredients may seem small but they signal consumer demand pulling policy toward cleaner, plant-based alternatives.

Hims & Hers Health offers cheapest GLP-1 weight-loss pill in US
A major pricing disruption move that puts pressure on Novo Nordisk and Eli Lilly.
The GLP-1 wars are moving from innovation to distribution and pricing.

✨ My Big Takeaway

Three patterns are emerging:

1. AI is shifting from tool to architecture.

2. Women’s health is finally being built intentionally.

3. Lifescience is becoming industrial policy, not just venture-backed experimentation.

The system is reorganizing itself.

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

This month felt like a convergence of three big forces: climate capital scaling in India, biotech industrializing fast, and AI creeping deeper into the scientific method itself. Here’s what stood out.

🌱 Climate & Industrial Bio

WestBridge Capital leads $45M funding in Varaha
Varaha is building carbon market infrastructure tied to regenerative agriculture, and this round signals real institutional belief in climate as a long-term asset class in India. My takeaway: climate is no longer impact-only; it’s becoming structured, measurable, and finance-driven.

Are Chinese (Industrial) Bio Companies Profitable?
A sharp breakdown of whether industrial biotech players in China are actually making money — or just scaling capacity. Important question. Industrial bio has always struggled with margins, so profitability (not just production scale) is the real signal to watch.

Why We Invested in EarthSync
An investor thesis piece by Theia Ventures explaining the bet on EarthSync. I always enjoy reading why capital moves, the “why” behind the check often reveals more about the future than the company itself.

🧬 Advanced Therapeutics & Infrastructure

Pandorum Technologies bags $18M to scale advanced tissue-repair therapies
Pandorum continues pushing regenerative medicine out of India, which isn’t easy. My takeaway: deep biotech in India is possible, but it requires patient capital and serious scientific credibility.

Cellares raises $257M Series D led by BlackRock and Eclipse
This is one of the more important stories this week. Automation of cell therapy manufacturing could unlock scalability in a space that’s historically bottlenecked by complexity and cost. We don’t need more cell therapy ideas, we need infrastructure.

Biotech Venture Needs a New Structure
A provocative take arguing that biotech VC as we know it may not be optimized for today’s science cycles. I agree with the spirit; long timelines and binary risk don’t always fit traditional fund models.

🤖 AI x Science

Stanford duo joins AI scientist race with startup backed by Andreessen Horowitz and Menlo Ventures
Another “AI scientist” startup enters the arena. We’re watching the early formation of a new category: autonomous hypothesis generation. The real question isn’t whether AI can assist it’s whether it can meaningfully originate discovery.

🧠 Bioelectricity & Systems Thinking

The Bioelectric Tech Stack
This piece reframes bioelectricity as a layered technology stack: sensing, modulation, data, control systems. It’s a reminder that biology isn’t just biochemical it’s electrical, computational, and dynamic.

Mental Health Needs Logistics, Not Better Science
This one hit. The argument: we don’t necessarily need breakthrough neuroscience, we need better delivery systems, operations, and access. I think this applies broadly across healthcare. Innovation is often operational, not molecular.

🧬 Synthetic Biology & National Strategy

Colossal Biosciences and the United Arab Emirates launch a Biovault at the Museum of the Future
Colossal continues blending de-extinction science with global partnerships. This feels less like a startup move and more like biotech becoming geopolitical infrastructure.

Also big shoutout to all of y’all who also follow me here, we recently hit 26k so thank you! If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

A lot of companies in 2025 were valued like software - despite having no human data. Others, with solid biology and disciplined execution, were ignored because they weren’t “platform enough,” “AI enough,” or loud enough.

2026 marks a reset.

Not because science suddenly gets easier; but because capital, acquirers, and public markets are re-aligning around biological truth. Risk, time, and proof are being priced explicitly again.

Below are the core life-science predictions shaping 2026 and what they mean globally, and for India in particular.

1. Dual exits become the default: M&A and IPOs converge

Big Pharma faces a structural problem: a patent cliff estimated at $200–230B in lost revenues between 2025–2030 as blockbuster drugs lose exclusivity. Internal R&D alone cannot refill pipelines at that scale.

This creates a permanent, non-cyclical demand to buy biology: through acquisitions, licensing, and strategic investments.

At the same time, public markets (when open) are selectively rewarding companies with:

• Late-stage assets

• Clear human proof-of-concept

• Clean regulatory narratives

The result: IPO and M&A are no longer competing outcomes. They are parallel options.

In 2026, the companies that win are deliberately designed for both.

How founders should build for dual exits

• Programs structured to be cleanly carve-out-able: single assets or tight franchises with defensible IP

• Pipelines sequenced so one “hero asset” hits a clear inflection point (IND, FIH, Phase 2 signal) within timelines public investors understand

• Data packages aligned to regulatory and payer questions, not just mechanistic novelty

A common pattern: one asset optimized for acquisition readiness, with earlier or platform assets preserved as IPO upside.

2. Proof beats platforms: biology is repriced

The biggest shift heading into 2026 is not technological (for the most part), it is financial.

For years, platforms with little or no human data were priced as if scalability itself reduced biological risk. That assumption has broken.

In 2026, human proof-of-concept becomes the exchange rate.

Investors and acquirers now ask a brutally simple question:

What is the probability this works in humans — and how soon will we know?

As capital becomes more selective, the market rewards:

• Clear pharmacodynamic or biomarker signals

• Early efficacy in defined populations

• Programs that reduce uncertainty quickly

Platforms might still matter but only after at least one asset proves itself in people.

This repricing favors execution over narrative, and speed-to-truth over theoretical breadth.

3. Clinical execution becomes the real moat

Scientific differentiation still matters but in 2026, how fast and cleanly you generate clinical data matters just as much.

As we all know, China has emerged as a global center for cost- and time-efficient early-phase trials, particularly in oncology and immunology:

• Per-patient costs can be 2–3x lower than the US in certain settings

• Regulatory timelines are explicitly optimized for speed

• Dense hospital networks enable rapid recruitment

Leading teams increasingly treat China not just as a market, but as clinical infrastructure for early signal generation.

However, execution is no longer just about cost.

Governance, data integrity, IP protection, and geopolitical risk now shape how trials are structured, where data lives, and how programs bridge into global development.

The moat in 2026 is not geography; it is repeatable, regulator-ready clinical execution.

4. Infrastructure matters — but it stays invisible

While digital tooling and AI continue to evolve, their role in life sciences is changing.

In 2026, the infrastructure that matters most is not flashy. It quietly:

• Cleans and governs complex biological and clinical data

• Improves trial operations, monitoring, and quality

• Compresses timelines without compromising regulatory credibility

AI is increasingly embedded into execution not positioned as the product itself.

Biology remains the protagonist. Infrastructure simply reduces friction.

5. A new healthcare segment emerges

A subtle but important shift is underway.

Healthcare is no longer defined only by sick patients.

A new healthcare segment is emerging: healthy, paying users who engage continuously with preventive care - turning episodic medicine into a longitudinal relationship.

This has implications across:

• Preventive health

• Digital biomarkers

• Medtech–biotech convergence

• New insurance and reimbursement structures

In 2026, some life-science companies will start looking less like drug developers — and more like health infrastructure businesses.

6. What this means for India in 2026

India is gradually transitioning from a services-led life-science economy to an innovation-led one.

National and state-level initiatives are pushing:

• Translational research

• Faster clinical approvals

• Funding for early-stage biotech

India’s advantage is not about copying the US or competing directly with China.

It lies in combining:

• Capital-efficient R&D

• Large and diverse patient populations

• English-speaking investigators

• Growing emphasis on regulatory-grade data

As global sponsors seek diversification of geopolitical and supply-chain risk, India can position itself as:

• A complementary clinical execution hub

• A capital-efficient proof-of-concept engine

• A credible acquisition pipeline for global pharma

When biology is priced on proof, speed, and clarity, India’s strengths align naturally.

7. How to build for 2026

For founders and investors, the 2026 compass is clear:

• Design assets so they can credibly exit via either M&A or IPO

• Treat clinical execution as a core competency, not a backend function

• Prioritize the fastest, cleanest route to first human proof

• Use infrastructure to reduce friction — not to replace biological rigor

2026 will not reward louder stories or broader platforms.

It will reward teams who understand one thing:

Biology doesn’t scale. Proof does.

References

1. Kadan M. Key CDMO market trends for 2025 and outlook for 2026. Vector BioMed. https://vectorbiomed.com/resource/what-economic-or-market-trends-are-having-the-biggest-impact-on-cdmo-capacity-and-pipelines-in-2025-and-what-will-2026-bring/.

2. Navigating 2026: Top 10 health technology trends every leader must know. LinkedIn. https://www.linkedin.com/pulse/navigating-2026-top-10-health-technology-trends-every-leader-twkwc/.

3. Pharmaceutical and life sciences: US deals 2026 outlook. PwC. https://www.pwc.com/us/en/industries/health-industries/library/pharma-life-sciences-deals-outlook.html.

4. Big ideas 2026: Part 1. Andreessen Horowitz (a16z).

a16z

Big Ideas 2026: Part 1

Nation | Technology | Opinion | Culture | Charts…

Read more

9 months ago · 625 likes · 25 comments · a16z New Media

5. Cheatham M. Breyer Capital 2026 healthcare and life sciences outlook.

Morgan's Newsletter

Breyer Capital 2026 Healthcare and Life Sciences Predictions

Each year at Breyer Capital, we take an intentional inventory of what has changed—from global market economies to scientific discoveries to shifts in the regulatory apparatus. This past year, we also published our updated Healthcare and Life Sciences thesis…

Read more

7 months ago · 27 likes · 3 comments · Morgan Cheatham

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India and/or globally.

💸 Arbiter raises $52M at a $400M valuation

I love AI in healthcare, but these valuations always make me wonder if we’re pricing possibility, not proof.
Read →

💊 Eli Lilly officially crosses $1T

The GLP-1 wave is wild. But whenever pharma celebrates a trillion-dollar moment, I can’t help thinking about how uneven innovation incentives really are.
Read →

🧭 Pfizer’s post-COVID plan

Big vision, sure - but I’m still not convinced pharma is ready to take real R&D risks again.
Read →

🧠 Aspen Neuroscience raises $115M for Parkinson’s cell therapy

Neurodegeneration deserves this momentum. But scaling cell-based therapies is a beast.
Read →

🩺 Function Health lands $298M, now valued at $2.5B

AI + primary care continues to explode. Still unsure if user retention will match investor optimism.
Read →

🧪 Terray Therapeutics pushes experiment-driven ML in small molecules

A company focusing on actual data generation (finally?), not fluffy AI language.
Read →

🤖 BenchSci partners with Mila

Biological inference is so underrated. Excited but waiting for real outputs beyond PR.
Read →

🧬 Cellarity unveils a new drug-safety prediction approach

If this works at scale, it could be a quiet revolution. But “breakthrough” gets thrown around too easily.
Read →

📰 “Dear Biotechs — Big Pharma Doesn’t Care” by Matt Shlosberg

This one hit differently. It basically says: big pharma isn’t built to nurture transformative innovation — it’s built to maximize predictable returns.
I agree. As someone watching India’s ecosystem grow, this makes me think a lot about incentives, long-termism, and who actually gets cures to the finish line.

Read →

Matt Shlosberg

Dear biotechs: Big Pharma doesn't care about you

Biotech is a strange world. On the one hand, you have brilliant scientists imagining a better future — a future full of pristine molecular constructs, elegantly binding targets, and curing humanity of all its ailments. On the other hand, you have Big Pharma: a collection of very large, very slow, very political organizations whose internal chaos is only…

Read more

9 months ago · 8 likes · Matt Shlosberg

Also big shoutout to all of y’all who also follow me here, we recently hit 18k so thank you! If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Subscribe now

hi everyone, it’s been a minute. I’ve been off my game here, but that doesn’t mean I haven’t been reading. My bookmarks are overflowing, so I figured I’d start November with a few that really made me pause, think, or just go “wow.”

Here’s what caught my eye 👇

💡 NovoFlow’s vision for AI in healthcare

Read →
AI in healthcare is moving fast—but NovoFlow stood out because they’re not just using AI to assist doctors, they’re trying to redesign the entire care flow. I love seeing companies go beyond the “AI for diagnosis” trope.

🧠 Hertility’s GynAI

Read →
This one made me smile. The world’s first AI trained exclusively on women’s health data. Finally, someone is treating female biology as the norm, not the exception. As someone who cares deeply about women’s health innovation—this is the kind of move that changes the narrative.

🧬 Manifold Bio x Roche

Read →
Brain delivery has always been biotech’s toughest nut to crack. Seeing Roche partner with a synthetic biology startup on brain “shuttles” makes me think we’re inching closer to meaningful neuro breakthroughs.

🧫 Dewpoint Therapeutics’ orphan drug nod

Read →
Phase separation biology was hyped a few years back, but this FDA orphan drug designation feels like the science is finally maturing into something tangible.

🧠 Mapping the developing brain

Read →
The Allen Institute dropped the first drafts of developing mammalian brain cell atlases. Foundational, yet underrated work. It’s projects like these that quietly shape the next decade of neuroscience.

💰 Azalea Therapeutics launches with $82M

Read →
Engineering cells inside the patient rather than outside the lab? Wild. If Azalea can pull this off, it could completely shift how we think about manufacturing cell therapies.

🌏 Asia keeps the biotech momentum going

• China’s unstoppable innovation wave

• Roche’s $1B+ deal with a Chinese biotech
  China isn’t waiting around. The speed and scale at which Chinese companies are commercializing science is honestly unmatched. There’s a lot to learn here for India too.

⚠️ Gene editing, risk, and reality

Read →
A tragic update: patient death in a CRISPR trial. It’s a stark reminder that while innovation moves fast, patient safety frameworks need to evolve just as quickly.

💊 J&J’s oncology expansion

Read →
J&J quietly continues to cement its leadership in oncology. Sometimes consistency wins over flash.

⚙️ NVIDIA x Eli Lilly’s “AI Factory”

Read →
Honestly, this might be my favorite read of the bunch. Pharma is moving from “AI-enabled” to “AI-structured”—and the concept of an AI factory could change R&D forever.

🇯🇵 Japan’s new biopharma playbook

Read →
Japan’s shift toward data-driven partnering instead of in-house pipelines feels smart. It’s a quieter, more collaborative way to innovate and maybe the model India’s biotech ecosystem should explore next.

Also big shoutout to all of y’all who also follow me here, we recently hit 16k so thank you! If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Subscribe now

👓 FDA clears 1st eyeglasses to slow childhood myopia

The FDA has cleared EssilorLuxottica’s innovative eyeglasses designed to slow the progression of nearsightedness in children—a milestone in pediatric eye care.
Childhood myopia is rising globally, especially in Asia, and traditional solutions like glasses and contact lenses only correct vision, not slow its decline. This approval signals a shift toward early intervention products in eye health—a trend I expect to see mirrored in other areas of preventive medicine.
Read more →

💼 Biotech Layoff Tracker 2025

The industry continues to face workforce challenges. Heidelberg has cut 75% of its headcount, while Biogen announced more team reductions.
Layoffs reflect the ongoing recalibration in biotech, where capital is scarcer and companies are being forced to prioritize lean operations. This is tough for talent but also creates opportunities for startups to scoop up experienced scientists and operators.
Full story →

🤖 Embodied AI in Biotech: Why China Could Lead

China is positioning itself at the forefront of the embodied AI revolution in biotech where AI agents don’t just analyze but actively drive scientific discovery.
We often think of AI in biotech as “paper reading” tools. Embodied AI goes a step further: enabling AI to run experiments. If China can scale this, it could leapfrog traditional R&D bottlenecks. For India and the US, it’s a reminder that investing in AI-driven lab infrastructure is no longer optional but its the next race.
Full story →

💰 BacAlt Biosciences raises ₹18 Cr (≈ $2.2M)

Avaana Capital led the funding round valuing BacAlt Biosciences at $8M, fueling growth in the Indian biotech ecosystem.
It’s exciting to see early-stage biotech in India attract institutional backing. At $8M valuation, BacAlt’s journey reflects how Indian biotech startups are still in nascent funding stages compared to the US but momentum is building. Watch this space for more capital flowing into India’s health innovation ecosystem.
Read more →

🌸 Visana Health raises $24M for Women’s Health Clinics

Visana Health secured fresh capital to expand its comprehensive women’s health clinics, bringing more accessible care solutions to market.
Women’s health remains underfunded globally, so $24M into care delivery is a big win. What excites me is Visana’s integrated clinic model, combining digital and in-person care exactly what’s needed to close the gap in women-specific healthcare.
Full article →

🌏 Asia’s Role in Longevity Biotech

Asia is emerging as a key hub for longevity biotech innovation, with research, funding, and ecosystems aligning to tackle aging head-on.
The longevity sector is often dominated by US and European players, but Asia is catching up fast. With its demographic challenges and strong government-backed science ecosystems, Asia could become the testing ground for scalable anti-aging solutions. India in particular has an opportunity to combine Ayurveda with modern longevity science.
Read the analysis →

Also big shoutout to all of y’all who also follow me here, we recently hit 10k so thank you! If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Subscribe now

This week’s roundup is a mix of breakthrough science, big pharma wins, femtech momentum, and the always-fascinating world of venture capital. Here’s what stood out to me and why -

🧬 Science & Research

Generating Novel Bacteriophages with Genome Language Models, DNA Aptamers for Fertility Tracking, and More
This Decoding Bio issue packs in some futuristic science: using genome language models to design bacteriophages, leveraging DNA aptamers for fertility tracking, and probabilistic inference in mice. My favorite highlight? The discussion on GEM-1 for transcriptomics, a step toward better predictive power in gene expression studies.
🔗 Read here

The mRNA Revolution: Beyond COVID
We’ve all seen how mRNA changed the game with COVID, but this piece dives into what’s next: cancer, flu, and even herpes vaccines. It’s a reminder that we’re only scratching the surface of mRNA’s potential.
🔗 Read here

💊 Pharma & Therapeutics

Merck’s Subcutaneous Keytruda Approval
Merck just scored FDA approval for a subcutaneous version of Keytruda. My takeaway: this is more than convenience, it’s about patient experience and protecting blockbuster market share in a crowded oncology space.
🔗 Read here

🚀 VC & Funding Insights

VC Math in Agrifood Tech
Loved this one - it breaks down the harsh math of what it takes for agrifood tech VCs to return a fund. A useful reality check if you’re building in a sector where exits are slower and harder to scale.
🔗 Read here

GG Ventures: $30M Fund for Women’s Health, Longevity & Sports
Finally, a dedicated fund backing categories often underinvested in. Women’s health + longevity + sports is a powerful thesis, and it’s great to see more capital flowing here.
🔗 Read here

Seven Starling Raises $8M for Women’s Mental Health
A femtech win! Seven Starling is expanding its mental health platform in the US. Women’s mental health still has huge unmet needs, and it’s exciting to see targeted solutions gain traction.
🔗 Read here

🌸 Femtech & Digital Health

Ultrahuman x Clue Partnership
Ultrahuman just partnered with Clue to bring menstrual cycle tracking into its Ring AIR. My takeaway: this integration makes wearables more holistic - moving beyond steps and sleep to real women’s health insights.
🔗 Read here

From subcutaneous oncology drugs to AI-designed bacteriophages and wearables that finally care about women’s cycles, the common thread is clear: the future of health is about accessibility + personalization. Whether it’s better delivery methods, smarter data, or funding for overlooked categories, the shift is toward meeting people where they are.

👉 If you’re curious about any of these topics or want to suggest articles for next week, drop me a comment or DM.

See you next week <3

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Subscribe now

Welcome to this week’s edition of my Life Science Weekly Reads - a curated stack of the biggest industry moves, fundraises, innovations, and perspectives shaping biotech globally and in India 🌍🔬

🔬 Diagnostics & Innovations

Exact Sciences Rolls Out Cancerguard Multi-Cancer Blood Test
Exact Sciences expands its portfolio in early cancer detection with Cancerguard, a non-invasive blood test that detects multiple cancer types early, aiming to improve patient outcomes through easier screening solutions.
🔗 Read more

⚖️ Regulatory Drama

FDA Misinterpreted Efficacy Data, Prompting DMD Therapy Rejection – Capricor Claims
Capricor Therapeutics, a biotech company, challenges the FDA’s decision to reject its cell therapy for Duchenne Muscular Dystrophy, citing misinterpretation of efficacy data. This highlights the ongoing tension between innovation and regulatory scrutiny in biotech.
🔗 Read more

🚀 Venture Capital & Funding

Venture Capital for Life Scientists – Chapter 1
A must-read for life science founders, this practical guide explains the VC world through the eyes of a scientist, covering fundraising, deal terms, and investor expectations.
🔗 Read more

RA Capital's Triple-Comma Queens
A fascinating profile on the women leaders at RA Capital reshaping venture capital in life sciences, offering lessons on diversity and investment strategy.
🔗 Read more

India Needs a Deeptech Fund, Not Just a Startup Fund
A strong argument for India to establish dedicated deeptech funds, focusing on long-term scientific innovation rather than early-stage consumer-focused startups.
🔗 Read more

🧬 Research & Science

Fluctuating DNA Methylation Tracks Cancer Evolution at Clinical Scale
A groundbreaking Nature study demonstrates how DNA methylation changes can be used to monitor cancer progression in real-time, potentially revolutionizing personalized treatment strategies.
🔗 Read more

🇮🇳 India Pharma & Agri-Tech

GST Council’s 56th Meeting: A Pivotal Development for India’s Pharma Sector
The latest GST council meeting introduces critical changes impacting the pharma industry’s tax and regulatory environment, shaping future business strategies in India.
🔗 Read more

ICL and BioPrime Partner to Tackle Phosphorus and Zinc Deficiency in Indian Soils
An important collaboration addressing micronutrient deficiencies in Indian agriculture, advancing sustainable farming practices and improving crop yields in the long term.
🔗 Read more

That wraps up this week’s stack. The lifescience ecosystem is clearly accelerating in India and globally, and these fundraises, alliances, and tech innovations are reshaping how the future of science is made.

👉 If you’re curious about any of these topics or want to suggest articles for next week, drop me a comment or DM.

See you next week <3

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Subscribe now

Welcome to this week’s edition of my Life Science Weekly Reads - a curated stack of the biggest industry moves, fundraises, innovations, and perspectives shaping biotech globally and in India 🌍🔬

🚀 Industry Growth & Ecosystem Developments

🇮🇳 Centre Launches Network of Integrated Biotech Centres

Link
India is doubling down on biotech innovation with a national network that bridges startups, industry, and academia. This integrated model aims to accelerate applied research and foster homegrown solutions in drug development, diagnostics, and synthetic biology.
💡 A step toward India becoming a true biotech innovation hub beyond services and manufacturing.

💸 US & Indian VCs Form $1B+ Deep Tech Alliance

Link
A major move as US and Indian VCs join forces to fuel India’s deep tech startups. With $1B+ in backing, this alliance will target early-stage companies in AI, biotech, quantum computing, and more.
💡 Deep tech in India is finally moving from ambition to capital-backed reality.

💰 Big Deals & Fundraises

🌿 Enveda Biosciences Raises $150M to Advance Nature-Inspired Drug Platform

Link
Enveda continues to push the frontier of nature-inspired drug discovery with a massive $150M raise, focusing on leveraging biology and machine learning to identify new therapeutic compounds from natural sources.
💡 The convergence of AI and natural product chemistry could potentially become biotech’s next frontier.

❤️ Novartis Licenses Heart Drugs from China’s Argo for $5.2B

Link
Novartis continues to strengthen its cardiovascular pipeline by licensing promising heart drug candidates from Argo Biotech in China in a $5.2 billion deal.
💡 So many lessons to learm from how China has been scaling their biotech economy.

🌱 Deep Dive: Synthetic Biology & Climate

🌡️ Synthetic Biology for Carbon and Climate

Link
A thoughtful analysis of how synthetic biology can reshape solutions for climate challenges: from carbon capture to sustainable materials.
💡Synthetic biology’s promise isn’t just pharma-focused. It’s about building a circular bioeconomy. Great explanations and use cases of synthetic biology.

🧫 Virtual Cell Simulations for Practical Applications

Link
An excellent exploration of how virtual cells are being designed to solve real-world problems, from optimizing bioprocesses to predicting drug responses.
💡 Virtual cells could be the unsung heroes enabling faster R&D and lower experimental costs in biotech.

🔔 That wraps up this week’s stack. The lifescience ecosystem is clearly accelerating in India and globally, and these fundraises, alliances, and tech innovations are reshaping how the future of science is made.

👉 If you’re curious about any of these topics or want to suggest articles for next week, drop me a comment or DM.

See you next week <3

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.

Welcome to my weekly nerding-out reads in the world of life sciences 🌍🧬. I’m experimenting with structure and sharing not just the biggest stories, but also my takeaways to connect the dots. These are reads I have come across that have helped me stay updated and/or learn more about the space!

💰 Deal Making

AbbVie acquires Gilgamesh’s Bretisilocin
Link
AbbVie is doubling down on neuroscience by acquiring Bretisilocin, a novel MDD therapy. Psychiatry hasn’t seen many blockbuster-level deals recently, so this signals renewed pharma interest in mental health.
Takeaway: Big Pharma wants to own the next-generation psychiatry pipeline before it matures.

Novo Nordisk bets $550M on Replicate Research
Link
Novo is already dominating obesity, but it knows GLP-1s won’t last forever. This deal is about hedging with new biology.
Takeaway: Obesity is the new oncology: massive spend, massive competition, and whoever innovates fastest keeps the crown.

Wugen secures $115M for allogeneic CAR-T
Link
Off-the-shelf CAR-T remains the holy grail. Wugen’s raise shows investors still back cell therapy, if it comes with scalability.
Takeaway: Allogeneic CAR-T is still alive, but companies need strong clinical momentum to convince the market. Anything related to scalability also reminds of how India can be playing a major role in helping that part of the value chain.

🌏 India Watch

India launches its first National Biofoundry Network
Link
India marked one year of the BioE3 Policy with the launch of the BioE3 Youth Challenge and the country’s first National Biofoundry Network.
The bioeconomy has surged from $10B (2014) to $165.7B (2024), aiming for $300B by 2030. Milestones include India’s first Biomanufacturing Institute, new bio-AI hubs, and 2,000+ proposals in advanced biotech areas.
Takeaway: BioE3 is positioning biotechnology as a major engine for India’s economy, jobs, and sustainability.

India–UAE Biotech Corridor
Link
Strategic tie-ups are happening beyond oil, with biotech becoming the new economic bridge.
Takeaway: The India–Middle East corridor could become as important for biotech as it has been for energy.

🧪 Clinical Data in the Spotlight

· $CRSP: Growing adoption of CASGEVY for SCD + P1 data for CTX310 in Lp(a).
Lp(a) could be a sleeper blockbuster.

· $NTLA: 3-year follow-up in in vivo HAE trials = elimination of attacks with one dose.
Durability matters; this is big validation for in vivo editing.

· $SANA: 6-month HIP data in T1D shows islet transplant without immunosuppression.
Could rewrite how we think of cell therapy for diabetes.

· $PRME: Positive P1/2 data in CGD with strong DHR positivity.
Platform credibility ↑ — efficient correction is translating clinically.

· $BEAM: Positive AATD data = clinical proof-of-concept.
Base editing isn’t just hype anymore.

⚖️ Obesity Watch

5 Obesity Assets That Failed
Link
Even in a hot space, failure is everywhere. This rundown reminds us that obesity drug dev is full of traps-safety, tolerability, and patient adherence challenges persist.
Takeaway: Don’t let Novo’s success fool you. The obesity race is a high-stakes minefield.

📚 Deeper Reads

Rewriting the Biotech Venture Playbook
Link
A sharp piece on how biotech VC is evolving. Worth a read if you’re thinking about incentives in early-stage investing.

Why Companies Still Flock to the US
Link
A perspective on why so many biotechs want a US footprint. Funding, ecosystem, regulatory pull but it ALWAYS comes with trade-offs.

💡 That’s it for this week. My aim with this series is to track not just the news, but the patterns shaping global biotech.

See you next week!

If you are someone who is interested/building/an expert in the Life Science startup ecosystem in India and/or the US, I would love to connect on LinkedIn or Instagram. Every couple of weeks, I highlight founder stories or talk about the infrastructure for life science in India.